Lévesque, Eric
Labriet, Adrien
Hovington, Hélène
Allain, Éric P.
Melo-Garcia, Luciana
Rouleau, Michèle
Brisson, Hervé
Turcotte, Véronique
Caron, Patrick
Villeneuve, Lyne
Leclercq, Mickaël
Droit, Arnaud
Audet-Walsh, Etienne
Simonyan, David
Fradet, Yves
Lacombe, Louis
Guillemette, Chantal
Funding for this research was provided by:
Prostate Cancer Canada
Cancer Research Society
Fonds de Recherche du Québec-Société et Culture
Article History
Received: 5 August 2019
Revised: 18 December 2019
Accepted: 23 January 2020
First Online: 12 February 2020
Ethics approval and consent to participate
: All participants provided written informed consent, and the CHU de Quebec research ethics committee approved the research protocol (#2012-362), and the study was performed in accordance with the Declaration of Helsinki.
: None.
: The data sets analysed during this study are available from the corresponding author on reasonable request.
: The authors declare no competing interests.
: This work was supported by research grants from the Prostate Cancer Canada (to E.L.), the Cancer Research Society (to C.G.), the Canada Research Chair Program (to C.G.) and the Fonds de Recherche du Québec-Santé (FRQ-S) Innovation fund to the CHU Research Centre (to C.G., E.L., L.L. and Y.F.). E.L. was the recipient of a Prostate Cancer Canada Rising Star Award (RS2013-59). E.L. was the holder of a CIHR Clinician–Scientist Award. CG holds a CIHR Canada Research Chair in Pharmacogenomics.